AbCellera appoints Lynn Seely to board of directors
The company named Seely, former Myovant and Medivation chief, an independent Class III director effective June 30, 2026.
AbCellera Biologics Inc. announced on July 6, 2026 the appointment of Lynn Seely, M.D., to its Board of Directors as an independent director. The Board of Directors of AbCellera Biologics Inc. appointed Lynn Seely, M.D as a new Class III director on June 30, 2026.1 She will serve until the company's 2029 annual meeting of shareholders and until her successor is duly elected and qualified, or until her earlier resignation or removal.1
The Board affirmatively determined that Dr. Seely is independent under the rules of The NASDAQ Stock Market LLC and the company's Corporate Governance Guidelines.1 Dr. Seely has not been appointed to serve on committees of the Board.1 Her compensation will follow the company's Non-Employee Director Compensation Policy, on the same terms as other non-employee directors, as previously disclosed in the company's Definitive Proxy on Schedule 14A filed April 29, 2026.1 The filing states Dr. Seely has no direct or indirect material interest in any transaction under Item 404(a) of Regulation S-K, and there are no arrangements or understandings between her and any other person related to her Board appointment.1
Seely's background spans several biopharmaceutical companies. She currently serves as president and CEO of Lyell Immunopharma Inc., a late-stage clinical company developing CAR T-cell therapies for hematologic malignancies and solid tumors.1 Previously she was president, CEO, board member, and first employee of Myovant Sciences Inc., where she helped commercialize Myfembree (relugolix, estradiol, and norethindrone acetate) and Orgovyx (relugolix).1 She also served as chief medical officer of Medivation Inc., leading clinical development of Xtandi (enzalutamide) prior to Medivation's $14 billion acquisition by Pfizer Inc.1
She previously served as lead independent director for Blueprint Medicines Corp. before its $9.1 billion acquisition by Sanofi, and was a member of the Board of Managers for TORL BioTherapeutics LLC.1 Dr. Seely received her M.D. from the University of Oklahoma College of Medicine.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.